We now offer online Metabolic Weight Loss programs and a virtual injection bar to support health goals. With more people staying home these days, commuting may have slowed, but mid-life weight gain continues (and actually worsens under stressful conditions).
Covid-stress aside, we know all too well that the incremental weight-creep is real: a woman entering menopause gains an average of 20-30 pounds of body fat over ten years, a pathological process known as redistribution. This process is a compensation for inappropriately low estrogen levels, a rise in androgen hormones, and the insulin resistance which ensues. Fat is translocated from subcutaneous and gluteo-femoral regions to the abdomen, leading to a phenomenon of menopausal metabolic syndrome. Without interventional endocrinology treatments combining medication, supplements, targeted nutrition and hormone therapy, reversing this progressive condition with diet and exercise alone is often elusive.
As women progress in age, their sources of estrogen change. Where once estradiol was released from the ovaries, post-menopausal women produce the vast majority of their estrogens from body fat tissue. While this change impacts the entire female body due to the near omnipresence of estrogen receptors, weight change and body composition are some of the most evident burdens of proof that women can visualize and literally hold in their hands. Estrogen promotes functionality of brown adipose tissue (which is metabolically active fat), and its absence enables brown fat to be readily converted into white fat (white fat which is resistant to weight loss efforts). Estrogen exerts unique actions on the mitochondrial machinery of the cell and impacts cellular utilization of glucose. Both hormonal deficiencies and fluctuations can promote insulin resistance, obesity and type II diabetes. Menopause changes metabolism, hypothalamic food intake and appetite regulation, and increases insulin synthesis, all of which promote increases in body fat.
Most doctors and clinicians remain unaware of the beneficial impacts of estrogen upon metabolism. On lab work, these changes are quantifiable using advanced lipid portfolio assessments, MPO, LP-PLA2, fasting insulin, fasting glucose, high-sensitivity C-reactive protein and hemoglobin A1C. These tests are uncommonly ordered by most providers, and even when they are, the effects of menopause upon these values are rarely contextualized into lab review appointments and personalized treatment plans. This quotidian situation presents quintessential missed opportunities to identify and reverse disease processes in women whose hormones are in flux. It is self-evident to our patients that healthcare as a whole is not updating itself rapidly enough to include these advances in metabolism. It is for reasons such as these that women inquire with our clinic to seek quality healthcare.
Dr. Parker's version of anti-aging medicine includes hormonal decline within the context of aging and disease, and works with you to correct depletions and deficiencies. She also works with women who are struggling with weight concerns which have arisen after using birth control pills, as well as with younger women whose diligent efforts of diet and exercise have not fructified into visceral fat loss.
Before you give up in frustration, please know we are here to help with novel approaches designed for safety and efficacy, and coach you through the rough spots. Yes, you can do this! You are not crazy (you just need to go to the right place.... )
Our 'Nurtured' program includes metabolic support, nutrient injections, dietary plans + discounts on the Peptide Upgrade option for stubborn mid-section body fat.
Combining the Metabolic Weight Loss program with injectable nutrients, peptides and non-stimulant appetite controlling medication has helped many of our patients realize body composition goals that have not previously been possible for them.
Després JP. Intra‐abdominal obesity: an untreated risk factor for Type 2 diabetes and cardiovascular disease. J Endocrinol Invest. 2006;29(3 Suppl):77‐82.
Faulds M, Zhao C, Dahlman-Wright K Gustafsson J-Å. / J Endocrinol. 2012; 212 (1): 3-12.
Hee Man Kim et al. Dia. Care. 2007, 30: 701-706
Pedersen S. B et al. J. Clin. Epidemiol. Metab. 2004, 89 (4): 1869–1878
Razmara L., Sunday C. et al. J. Pharmacol. Experim. Therap. 2008, 325 (3): 782–790
Suba Z. Drug Des. Devel. Ther. 2015, 9: 2663-2675
Toth MJ, Sites CK, Eltabbakh GH, et al. / Diabetes Care. 2000; 23: 801-806.
Copyright © 2020 Dr. Karen Parker ND. LLC, a specialty sub-division of Neurevolution Medicine LLC All Rights Reserved.
Powered by the Liila Monster Club